In terms of the molecular types, high expression of PBK/TOPK was observed in 9.10% (3/33), 41.88% (31/74), 55.1% (27/49), and 60.00% (18/30) of patients with luminal A type, luminal B type, HER-2(+) type, and triple negative breast cancer (TNBC), respectively (P < 0.001, Table 1). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.